Human Philadelphia chromosome-positive (Ph+) leukemias induced by the BCR-ABL oncogene, including chronic myeloid leukemia (CML) and B-cell acute lymphoblastic leukemia (B-ALL), are among the most common hematologic malignancies. The BCR-ABL tyrosine kinase inhibitor STI571 (Gleevec) is highly effective in treating chronic phase CML patients, but is much less effective in treating CML blast crisis and Ph+ B-ALL patients. Moreover, the emerging clinical resistance to STI571 begs for development of new therapeutic strategies. Determination of the key signaling pathways utilized by BCR-ABL to induce B-ALL is crucial for understanding the pathophysiology of the disease and for developing effective therapies. We have established efficient and accurate mouse models of human Ph+ leukemias to test our overall hypothesis that BCR-ABL induces both lymphoid and myeloid leukemias, but different signaling pathways are utilized in these two cell lineages. In support of this hypothesis, we identified three Src family kinases (Lyn, Hck, and Fgr) as key signaling molecules in the development of BCR-ABL-induced B-ALL but not CML (Nature Genetics 36,453-461, 2004). Therefore, we hypothesize that Src kinase signaling pathways in BCR-ABL-expressing lymphoid cells are different from those in myeloid cells. We have also found that inhibition of BCR-ABL kinase by STI571 does not reduce BCR-ABL-stimulated Src activation, whereas use of a Src kinase inhibitor reduces proliferation and induces apoptosis of BCR-ABL-expressing cells that are resistant to ST1571. These results suggest that the activation of Src kinases is independent of BCR-ABL kinase activity. Therefore, we further hypothesize that simultaneous inhibition of functions of both BCR-ABL kinase (by STI571) and Src kinases (by a Src kinase inhibitor) is needed for therapy of Ph+ B-ALL. To test these hypotheses, we will take biochemical and genetic approaches to study the molecular mechanism by which Src kinases are activated by BCR-ABL and are involved in BCR-ABL signaling in B-lymphoid cells and B-ALL development. We will also further evaluate the use of Src kinases as therapeutic targets for B-ALL using our mouse model.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA114199-03
Application #
7221214
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Mufson, R Allan
Project Start
2005-04-07
Project End
2010-02-28
Budget Start
2007-03-01
Budget End
2008-02-28
Support Year
3
Fiscal Year
2007
Total Cost
$284,832
Indirect Cost
Name
Jackson Laboratory
Department
Type
DUNS #
042140483
City
Bar Harbor
State
ME
Country
United States
Zip Code
04609
Chen, Yaoyu; Peng, Cong; Abraham, Sheela A et al. (2014) Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. J Clin Invest 124:3847-62
Yang, Zhong-Fa; Zhang, Haojian; Ma, Leyuan et al. (2013) GABP transcription factor is required for development of chronic myelogenous leukemia via its control of PRKD2. Proc Natl Acad Sci U S A 110:2312-7
Zhang, Haojian; Peng, Cong; Hu, Yiguo et al. (2012) The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat Genet 44:861-71
Zhang, Haojian; Li, Huawei; Xi, Hualin S et al. (2012) HIF1? is required for survival maintenance of chronic myeloid leukemia stem cells. Blood 119:2595-607
Peng, Cong; Chen, Yaoyu; Shan, Yi et al. (2012) LSK derived LSK- cells have a high apoptotic rate related to survival regulation of hematopoietic and leukemic stem cells. PLoS One 7:e38614
Zhang, Haojian; Li, Huawei; Ho, Ngoc et al. (2012) Scd1 plays a tumor-suppressive role in survival of leukemia stem cells and the development of chronic myeloid leukemia. Mol Cell Biol 32:1776-87
Sullivan, Con; Chen, Yaoyu; Shan, Yi et al. (2011) Functional ramifications for the loss of P-selectin expression on hematopoietic and leukemic stem cells. PLoS One 6:e26246
Chen, Yaoyu; Sullivan, Con; Peng, Cong et al. (2011) A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia. Blood 118:390-400
Sullivan, Con; Peng, Cong; Chen, Yaoyu et al. (2010) Targeted therapy of chronic myeloid leukemia. Biochem Pharmacol 80:584-91
Chen, Yaoyu; Peng, Cong; Sullivan, Con et al. (2010) Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Anticancer Agents Med Chem 10:111-5

Showing the most recent 10 out of 22 publications